10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2009 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Sales | $ 27,428,300 | 23,850,300 | 24,197,700 |
| Costs, Expenses and Other | |||
| Materials and production | 9,018,900 | 5,582,500 | 6,140,700 |
| Marketing and administrative | 8,543,200 | 7,377,000 | 7,556,700 |
| Research and development | 5,845,000 | 4,805,300 | 4,882,800 |
| Restructuring costs | 1,633,900 | 1,032,500 | 327,100 |
| Equity income from affiliates | (2,235,000) | (2,560,600) | (2,976,500) |
| U.S. Vioxx Settlement Agreement charge | 0 | 0 | 4,850,000 |
| Other (income) expense, net | (10,669,500) | (2,318,100) | (75,200) |
| Total Costs, Expenses and Other | 12,136,500 | 13,918,600 | 20,705,600 |
| Income Before Taxes | 15,291,800 | 9,931,700 | 3,492,100 |
| Taxes on Income | 2,267,600 | 1,999,400 | 95,300 |
| Net Income | 13,024,200 | 7,932,300 | 3,396,800 |
| Less: Net Income Attributable to Noncontrolling Interests | 122,900 | 123,900 | 121,400 |
| Net Income Attributable to Merck & Co., Inc. | 12,901,300 | 7,808,400 | 3,275,400 |
| Preferred Stock Dividends | 2,100 | 0 | 0 |
| Net Income Available to Common Shareholders | 12,899,200 | 7,808,400 | 3,275,400 |
| Basic Earnings per Common Share Available to Common Shareholders | 5.67 | 3.65 | 1.51 |
| Earnings per Common Share Assuming Dilution Available to Common Shareholders | 5.65 | 3.63 | 1.49 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2009 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 13,024,200 | 7,932,300 | 3,396,800 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Gain related to Merck/Schering-Plough partnership | (7,529,600) | 0 | 0 |
| Gain on disposition of interest in Merial Limited | (3,162,500) | 0 | 0 |
| Gain on distribution from AstraZeneca LP | 0 | (2,222,700) | 0 |
| Equity income from affiliates | (2,235,000) | (2,560,600) | (2,976,500) |
| Dividends and distributions from equity affiliates | 1,724,300 | 4,289,600 | 2,485,600 |
| U.S. Vioxx Settlement Agreement charge | 0 | 0 | 4,850,000 |
| Depreciation and amortization | 2,576,000 | 1,631,200 | 1,988,200 |
| Deferred income taxes | 1,820,200 | 530,100 | (1,781,900) |
| Share-based compensation | 415,500 | 348,000 | 330,200 |
| In-process research and development | 0 | 0 | 325,100 |
| Taxes paid for Internal Revenue Service settlement | 0 | 0 | (2,788,100) |
| Other | (534,200) | 607,800 | (186,100) |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 165,200 | (889,400) | (290,700) |
| Inventories | 1,211,300 | (452,100) | (40,700) |
| Trade accounts payable | (45,200) | 0 | 117,700 |
| Accrued and other current liabilities | (4,003,500) | (1,710,900) | 451,100 |
| Income taxes payable | (364,800) | (465,300) | 987,200 |
| Noncurrent liabilities | 231,300 | (108,000) | 26,200 |
| Other | 98,800 | (358,300) | 105,100 |
| Net Cash Provided by Operating Activities | 3,392,000 | 6,571,700 | 6,999,200 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,460,600) | (1,298,300) | (1,011,000) |
| Purchases of securities and other investments | (3,070,800) | (11,967,300) | (10,132,700) |
| Proceeds from sales of securities and other investments | 10,941,900 | 11,065,800 | 10,860,200 |
| Proceeds from sale of interest in Merial Limited | 4,000,000 | 0 | 0 |
| Schering-Plough merger, net of cash acquired | (12,842,600) | 0 | 0 |
| Acquisitions of businesses, net of cash acquired | (130,000) | 0 | (1,135,900) |
| Distribution from AstraZeneca LP | 0 | 1,899,300 | 0 |
| Increase in restricted assets | 5,547,600 | (1,629,700) | (1,401,100) |
| Other | 170,500 | 95,800 | 10,500 |
| Net Cash Provided by (Used by) Investing Activities | 3,156,000 | (1,834,400) | (2,810,000) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (2,422,000) | 1,859,900 | 11,400 |
| Proceeds from issuance of debt | 4,228,000 | 0 | 0 |
| Payments on debt | (25,300) | (1,392,000) | (1,195,300) |
| Purchases of treasury stock | 0 | (2,725,000) | (1,429,700) |
| Dividends paid to stockholders | (3,215,000) | (3,278,500) | (3,307,300) |
| Other dividends paid | (264,100) | (121,800) | (120,800) |
| Proceeds from exercise of stock options | 186,400 | 102,300 | 898,600 |
| Other | (126,300) | 32,600 | 277,000 |
| Net Cash Used by Financing Activities | (1,638,300) | (5,522,500) | (4,866,100) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 33,400 | (182,600) | 98,300 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 4,943,100 | (967,800) | (578,600) |
| Cash and Cash Equivalents at Beginning of Year | 4,368,300 | 5,336,100 | |
| Cash and Cash Equivalents at End of Year | 9,311,400 | 4,368,300 | 5,336,100 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2009 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2009 | Dec 31, 2008 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 9,311,400 | 4,368,300 |
| Short-term investments | 293,100 | 1,118,100 |
| Accounts receivable (net of allowance for doubtful accounts of $112.6 in 2009 and $58.5 in 2008) | 6,602,900 | 2,907,700 |
| Inventories (excludes inventories of $1,157.2 in 2009 and $587.3 in 2008 classified in Other assets - see Note 8) | 8,055,300 | 2,091,000 |
| Deferred income taxes and other current assets | 4,165,900 | 8,627,500 |
| Total current assets | 28,428,600 | 19,112,600 |
| Investments | 432,300 | 6,491,300 |
| Property, Plant and Equipment (at cost) | ||
| Land | 666,700 | 386,100 |
| Buildings | 12,210,300 | 9,767,400 |
| Machinery, equipment and office furnishings | 16,173,600 | 13,103,700 |
| Construction in progress | 1,817,500 | 871,000 |
| Property, Plant and Equipment, Gross | 30,868,100 | 24,128,200 |
| Less allowance for depreciation | 12,594,600 | 12,128,600 |
| Property,Plant and Equipment, Net | 18,273,500 | 11,999,600 |
| Goodwill | 11,923,100 | 1,438,700 |
| Other Intangibles, Net | 47,655,800 | 525,400 |
| Other Assets | 5,376,400 | 7,628,100 |
| Total Assets | 112,089,700 | 47,195,700 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 1,379,200 | 2,297,100 |
| Trade accounts payable | 2,236,900 | 617,600 |
| Accrued and other current liabilities | 9,453,800 | 9,174,100 |
| Income taxes payable | 1,285,200 | 1,426,400 |
| Dividends payable | 1,189,000 | 803,500 |
| 6% Mandatory convertible preferred stock, $1 par value Authorized - 11,500,000 shares; issued and outstanding - 855,422 shares | 206,600 | 0 |
| Total current liabilities | 15,750,700 | 14,318,700 |
| Long-Term Debt | 16,074,900 | 3,943,300 |
| Deferred Income Taxes and Noncurrent Liabilities | 18,771,500 | 7,766,600 |
| Merck & Co., Inc. Stockholders' Equity | ||
| Common stock, $0.50 par value - 2009; $0.01 par value - 2008 Authorized - 6,500,000,000 shares - 2009; 5,400,000,000 shares - 2008 Issued - 3,562,528,536 shares - 2009; 2,983,508,675 - 2008 | 1,781,300 | 29,800 |
| Other paid-in capital | 39,682,600 | 8,319,100 |
| Retained earnings | 41,404,900 | 43,698,800 |
| Accumulated other comprehensive loss | (2,766,500) | (2,553,900) |
| Stockholders' equity before deduction for treasury stock | 80,102,300 | 49,493,800 |
| Less treasury stock, at cost: 454,305,985 shares - 2009; 875,818,333 shares - 2008 | 21,044,300 | 30,735,500 |
| Total Merck & Co., Inc. stockholders' equity | 59,058,000 | 18,758,300 |
| Noncontrolling Interests | 2,434,600 | 2,408,800 |
| Total Equity | 61,492,600 | 21,167,100 |
| Total Liabilities and Stockholders' Equity | 112,089,700 | 47,195,700 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |